TELUS Health 2023 Drug Trends Report: Diabetes now the top drug category for claims; antidepressants surged for youth
TORONTO, June 13, 2023 (GLOBE NEWSWIRE) -- Today, TELUS Health issued its annual 2023 Drug Data Trends and National Benchmarks Report , revealing that diabetes has replaced inflammatory diseases, such as rheumatoid arthritis, as the top drug category for claims in Canada.
- TORONTO, June 13, 2023 (GLOBE NEWSWIRE) -- Today, TELUS Health issued its annual 2023 Drug Data Trends and National Benchmarks Report , revealing that diabetes has replaced inflammatory diseases, such as rheumatoid arthritis, as the top drug category for claims in Canada.
- “It is our hope that the findings in our 2023 Drug Trends Report will continue to offer private payors and benefits advisors valuable insights to help adjust and improve benefits plans,” said Martin Bélanger, Managing Director, Payor Solutions, TELUS Health.
- “The fact that growth in spend has been observed in a specific diabetes class of drugs suggests that existing claimants are switching to more costly therapies,” noted Lavina Viegas, Pharmacist, TELUS Health.
- Published annually since 2015, the TELUS Health Drug Data Trends and National Benchmarks Report is based on the claims data of the 2022 TELUS Health portfolio, and provides a contextual view of adoption rates of plan management trends to help insurers and employers alike understand major trends in prescription drug utilization.